Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.090 Biomarker disease BEFREE Newer antidiabetic drugs (SPPARMs, GLP-1 RA and SGLT2i) alone or in combination and acting alone or on the background of potent statin therapy which is recommended in T2DM, might contribute substantially to NAFLD/NASH amelioration, possibly reducing not only liver specific but also cardiovascular morbidity. 30961499 2020
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.090 Biomarker disease BEFREE In this review, we provide an overview of the role of GLP-1 and GLP-2 in lipid homeostasis and metabolic disease including NAFLD and NASH. 30578967 2019
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.090 Biomarker disease BEFREE More recently, there is an increasing interest regarding the effects of newer anti-diabetic drugs, such as dipeptidyl peptidase 4 inhibitors (DPP-4i), sodium glucose cotransporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on NAFLD/NASH. 31672448 2019
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.090 Biomarker disease BEFREE From this analysis, we can conclude that the multi-target beneficial action of the GLP-1 analogues could explain the positive effects observed in animal and human models on progression of NAFLD to NASH. 30359962 2018
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.090 Biomarker disease BEFREE The new anti-diabetic medication classes, the sodium-glucose co-transporter-2 inhibitors (SGLT2i) and the glucagon like peptide receptor agonists (GLP1 RA) for patients with NAFLD/NASH, CKD and T2DM are useful because they ameliorate NAFLD/NASH, delay the evolution of CKD, and substantially reduce CVD and all-cause mortality. 28676027 2018
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.090 AlteredExpression disease BEFREE Miglitol treatment suppressed HFHSD-induced NASH development with the suppression of hepatic Toll-like receptor 4 expression, increased glucagon-like peptide 1 (GLP-1) concentration, and reduced lipopolysaccharide concentration in portal plasma. 28349245 2017
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.090 Biomarker disease BEFREE We searched the MEDLINE, Embase, and Cochrane Library Central to identify randomized controlled trials (RCTs) and observational studies that compared GLP-1RAs with a control treatment or baseline values with respect to efficacy and safety in patients with NAFLD/NASH. 28065744 2017
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.090 Biomarker disease BEFREE GLP-1 analogues and SGLT-2 inhibitors are currently approved for use in diabetes, have shown early efficacy in NASH and also have beneficial cardiovascular effects. 28677333 2017
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.090 Biomarker disease BEFREE GLP-1 analogues could be a promising treatment approach to improve hepatic insulin resistance in patients with NAFLD/NASH. 21745271 2011